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Abstract 
Progress in bacterial therapy for cancer and infectious diseases is hampered by the absence of 
safe and efficient vectors. Sustained delivery and high gene expression levels are critical for 
the therapeutic efficacy. Here we developed a Salmonella typhimrium strain to maintain and 
safely deliver a plasmid vector to target tissues. This vector is designed to allow dual 
transcription of therapeutic factors, such as cytotoxic proteins, short hairpin RNAs or 
combinations, in the nucleus or cytoplasm of eukaryotic cells, with this expression sustained 
by an autocatalytic positive-feedback loop. Mechanisms to prime the system and maintain the 
plasmid in the bacterium are also provided. Synergistic effects of attenuated Salmonella and 
our inter-kingdom system allow the precise expression of Diphtheria toxin A chain (DTA) 
gene in tumor microenvironment and eradicate large established tumors in immunocompetent 
animals. In the experiments reported here, 26% of mice (n=5/19) with aggressive tumors were 
cured and the other all survived until the end of the experiment. We also demonstrated that 
ST4 packaged with shRNA-encoding plasmids has sustained knockdown effects in nude mice 
bearing human MDA-MB-231 xenografts. Three weeks after injection of 5×10
6
 
ST4/pIKT-shPlk, PLK1 transcript levels in tumors were 62.5 ± 18.6% lower than the vector 
control group (P=0.015). The presence of PLK1 5′ RACE-PCR cleavage products confirmed a 
sustained RNAi-mediated mechanism of action. This innovative technology provides an 
effective and versatile vehicle for efficient inter-kingdom gene delivery that can be applied to 
cancer therapy and other purposes. 
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1. Introduction 
The use of bacteria as therapeutic agents has become an increasingly important area of 
investigation. Their low cost, fast production, diverse natural and modified tropism profiles, 
high packaging capacity, coupled with their relative tolerance of the immune system and 
relative ease of control in the case of adverse events, make bacterial-mediated delivery an 
attractive alternative for gastrointestinal [1], respiratory [2], urogenital tracts [3] and solid 
tumors [4, 5]. Most studies use attenuated bacteria in some way to decrease virulence [6-8] 
and augment their natural cytotoxicity with vectors designed to deliver an agent to the target 
organs [9-15]. However, to date, clinical trials of bacterial mediated therapy have had modest 
results [5, 16]. Limiting factors include the bacterial virulence [17], the effects of host 
immune response to their presence [18], the efficiency of intracellular delivery of multiple 
agents to target cells, instability of the plasmid vector leading to its loss in the bacteria [19], 
and inefficient transport of expression plasmids [20] to the nucleus to ensure an optimal dose 
level of therapeutic agents [21].  
Using enhanced recombineering methods [22], we previously developed an “obligate” 
anaerobic Salmonella strain with enhanced host safety and anti-tumor activity [23, 24]. Here 
we build on that to develop a new platform that overcomes the above limitations while 
retaining some of its benefits. S. typhimurium strain SL7207, an aroA deficient strain [25] was 
used to engineer a series of Salmonella strains (Table S1) that have enhanced safety towards 
the host organism and an increased ability to deliver therapeutic payloads. We demonstrate a 
live microbe-based inter-kingdom system to deliver therapeutic vectors in a manner that does 
not compromise host safety and provides greatly improved stability, enhanced intracellular 
delivery and sustained expression of versatile therapeutic agents (including proteins or RNA 
molecules), which can target multiple gene networks.  
 Expression of the payloads is “primed” in mammalian cells through the transfer of both a 
therapeutic plasmid containing a foreign gene driven by dual promoters and an initial source 
of T7 RNA polymerase (T7 RNAP) enzyme, and propagated by an auto-feedback system. 
This therapeutic plasmid has been designed so that it can contain different payloads that are 
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capable of being expressed through both the cytoplasmic and nuclear systems in a mammalian 
cell and regulated by a feedback system. Maintenance of the plasmid in the bacterium is 
managed by relocating an essential bacterial gene infA from the bacterial chromosome onto 
the plasmid. It is the first report to date describing the design and use of a dual expression 
system incorporated with an amplification loop in gene therapy, which is based on an 
inter-kingdom interaction of bacteria and higher organisms. In vivo efficacy on tumor tissue 
and considerably improvement over existing techniques were demonstrated.  
 
2. Materials and methods 
2.1. Bacterial strains, animals, cell lines, enzymes and chemicals 
Salmonella typhimurium strain SL7207 was kindly provided by Dr. B.A.D Stocker. 
Strains and plasmids are described in Table S1. Six-week-old female nu/nu athymic and 
BALB/c mice were purchased from the Laboratory Animal Unit of the University of Hong 
Kong. The research protocols were approved by the Committee on the Use of Live Animals in 
Teaching and Research of the University of Hong Kong (CULATR 1685-08). Breast cancer 
cell line MDA-MB-231 (human) and 4T1 (mouse) were from the American Type Culture 
Collection and cultured under conditions specified by the manufacturer. Enzymes were from 
New England Biolabs and chemicals were from Sigma-Aldrich 
 
2.2. Construction of Salmonella mutants 
The λ-Red recombination system (plasmid pSim6; a gift from Dr. Donald Court) was 
used to make genetic manipulations. A PCR-amplified CM-T7 RNAP cassette was 
electroporated into recombination-competent SL7207 cells and selected on chloramphenicol 
Luria-Bertani (LB) plates. The correct colony was confirmed by PCR and subsequently 
self-excised the antibiotic resistance, generating ST1. For the integration of Listeriolysin O
（LLO）expression cassette, an integration vector backbone pYB-asd (a pBSK derivate with 1 
kb flanking regions of asd sites) was generated. The PsseA-hlyA and loxP-CM-loxP cassettes 
were ligated to NotI, XhoI and XhoI respectively, to construct plasmid pYB-asd-hlyA. Then 
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the CM-PsseA-hlyA genetic circuit was digested by KpnI and SacII and transformed into ST1 
cells induced for the λ-Red recombination to create strain ST2. Thirdly, a similar 
recombineering strategy was used to replace htrA gene by CM-PpepT-asd-sodA cassette in 
ST3. Fourthly, a ‘precise’ deletion of infA locus from ST3 has been performed. Plasmid 
pET28a-infA containing E.coli MG1655 infA expression cassette has been constructed and 
co-transformed with pSim6 into ST3. Strain ST5 was constructed similarly, but using GFP 
instead of LLO. A tetR selection cassette flanking with long homology arms of infA site was 
purified and transformed. PCR amplification of the new junctions between the drug marker 
and infA homology arm-flanking DNA was performed to confirm that the wild-type copy of 
infA was removed. The resulting strain ST4 was confirmed by colony PCR for site-specific 
integration of the targeting constructs (Table S2 and Fig. S1).  
 
2.3. In vitro studies 
Bacteria were harvested at the late logarithmic phase and then added at Multiplicity of 
infections (MOIs) ranging from 50 to 200 to cell monolayers. After 4 h, the cells were washed 
and grown for additional 24-72 h in complete medium containing 10 μg/ml of Gentamycin 
(Life Technologies). 
 Cells were arrested at G1 phase by double Thymidine block (at a concentration of 5 mM) 
or treated with 20 μg/ml Rifampicin, 1 μg/ml α-Amanitin or 1 μg/ml Cycloheximide to inhibit 
transcription or translation. To evaluate EGFP expression, total proteins were extracted by 
analysis buffer according to the GFP Quantization Kit (Biovision) and analysed by a 
Varioskan Flash spectral scanning multimode reader (Thermo Scientific). For quantification, 
the infected cells were detached and analysed by flow cytometry using a FACScalibur 
cytometer (Becton-Dickinson) and software WinMDI2.9.  
Cell viability was measured using 5-diphenyltetrazolium bromide (MTT) according to the 
producer's protocol. For apoptosis assay, cells were harvested and stained with Annexin-V/ 
Propidium iodide (PI) assay kit (BD Biosciences), followed by ﬂow cytometric analysis. 
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2.4. Tumor xenograft and in vivo studies 
10
6 
MDA-MB-231 cells or 10
5 
4T1 cells were subcutaneously injected to athymic (nu/nu) 
or BALB/c mice. Tumor volume (mm
3
) was determined by measuring length (l) and width 
(w) and calculating volumes (V=lw
2
/2). Total RNA and protein were extracted from 
xenografted tumors following excision. The remaining tissues were divided in two 
longitudinally: one part was fixed in 4% paraformaldehyde (PFA) for subsequent hostological 
examinations, or to isolate ST4. 
 
2.5. Real-time PCR quantification and western blot analysis 
Total RNA was extracted by using TRIzol® (Life Technologies). Contaminating DNA 
was removed with DNase I and cDNA was generated using Superscript III First-strand 
Synthesis kit (Life Technologies). Anchored oligo (dT)20 primer was used to hybridize to the 
poly (A) tail of mRNA transcribed from the nuclear system. Gene specific primers with an 
adapter were used to prime all the mRNA from both nuclear as well as cytoplasmic system. 
After cDNA synthesis, sequence-specific amplification was detected by a fluorescent signal 
of SYBR Green (ABI) by using Real-time PCR Detector (ABI7500). For western blotting, 
protein samples were separated on SDS-PAGE gels and then transferred to PVDF membranes 
(Millipore). Membranes were processed following the ECL western blotting protocol 
(Millipore).  
 
2.6. ELISA assay of Diphtheria toxin A subunit 
Briefly, 96-well plates were coated with a mouse anti-Diphtheria toxin A subunit 
(Maridian) monoclonal antibody in a dilution of 1:500 and blocked by PBS with 5% BSA. 
FLAG-tagged DT A chain was expressed by bacteria and purified by anti-FLAG M2 beads 
(Sigma-Aldrich). Protein concentration was determined by Bradford Reagent Assay. Tumor 
lysates were diluted in PBS with 2% BSA to concentrations within the liner range of the 
standard curve. A rabbit anti-FLAG antibody (Cell signalling) conjugated with horseradish 
peroxidase was used as the secondary antibody in a dilution of 1:8000.  
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2.7. Histology 
Mice were intraperitoneally injected with a hypoxyprobe-1 solution (60 mg/kg) 10~40 
min before euthanasia. Tissues were fixed in 4% PFA, paraffin embedded and sectioned into 
5 μm slices. Hypoxic regions were visualized by mouse anti-hypoxyprobe-1 antibody 
(Chemicon), Salmonella, Diphtheria toxin A subunit, Plk1 and CD105 were separately 
detected by Salmonella (Abcam), Diphtheria toxin A subunit (Maridian), Plk1 (Life 
Technologies) or CD105 (PharMingen) antibody. Bound primary antibodies were detected 
using fluorescence conjugated secondary antibodies (Life Technologie) or HRP-conjugated 
secondary antibodies which then developed in DAB solution (Daco). Standard 
hematoxylin-eosin (H&E) staining was performed to detect histopathologic changes. The 
TUNEL working procedure was carried out following the producer's directions (Roche). 
Pictures were taken under a fluorescence microscope or a light microscope. 
 
2.8. Culture of Salmonella ST4 from tissues 
Tissues were homogenized in PBS (1:10 w/v ratio) and 10 μl of diluted (10-1→10-5) 
homogenate were dropped on LB agar plates supplemented with 0.5 mM DAP and 25 μg/ml 
streptomycin. These plates were incubated at 37 ℃ and examined for the presence of 
colonies.  
 
2.9. 5’RACE assay for mRNA cleavage products 
After first-strand cDNA synthesis, TdT (Terminal transferase) (Life Technologies) and 
dCTP (Life Technologies) was used to append a poly C
+
-tail to the cDNA. Anchor primer 
UAP poly G and PLK1 GSP1 were used for the first around amplification of dC-tailed cDNA. 
Nested PCR was performed with 2 μl of the first reaction using the primer UAP and PLK1 
GSP2. PCR products were examined by gel electrophoresis, and then cloned into T simple 
vector (Takara) for sequencing.  
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2.10. Isolation of murine serum 
Murine blood was drawn into a serum vial and kept on ice. After congregation for 2 min 
at 16000×g, the supernatant serum was transferred in fresh tubes and stored -20°C for further 
use. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of 
mice were analysed by Reitman and Frankel method. Blood urea nitrogen (BUN) levels were 
determined by colorimetric method.  
 
2.11. Statistics 
Data are presented as mean ± standard deviation (SD). Statistical comparisons between 
two groups were evaluated by Student’s t-test and corrected by ANOVA for multiple 
comparisons. Statistical significance was defined as P values of < 0.05. A log-rand test was 
used to compare xenograft survival. Prism 5.0 (GraphPad Software) provided the software for 
statistical analysis.  
 
3. Results 
3.1. Development of an Inter-kingdom Dual Expression System 
S. typhimurium strain ST3 was engineered with multiple genetic modifications: (1) triple 
deletions of essential genes: infA for balanced-lethal host-vector system [26], and auxotrophic 
genes aroA, asd for further attenuation, (2) replacement of the asd gene with anaerobic 
control, (3) mutation of the colonic acid-producing gene gmd to preclude biofilm formation 
and enhance intracellular entry, (4) constitutive expression of T7 RNAP enzyme for priming 
transcription when the plasmid is delivered into the host cytoplasm, (5) intracellular 
expression of the pore-forming LLO (by replacing asd with hlyA gene from Listeria 
monocytogenes) to facilitate intracellular delivery of molecules to the host (Fig. S2). In vitro 
experiments demonstrated that ST3 could invade eukaryotic cells, break the endosomal 
compartment and directly release protein, plasmid DNA and translation-competent mRNA 
into the cytosol, leading to the desired gene expression (Fig. S3).  
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To develop a novel inter-kingdom dual expression (IKDE) system with a phage RNAP 
amplification circuit, a T7 RNAP-based cytoplasmic expression facility was added to the 
commonly used nuclear system. Transcription of the payloads is enabled by both T7 
(cytoplasmic) and CMV (nuclear) promoters to allow a dual expression in the cytoplasm and 
nucleus respectively. Insertion of a eukaryotic internal ribosome entry site (IRES) prior to the 
gene of interest was added to augment RNA processing, allowing a cap-independent 
translation of transcripts produced in the mammalian cytoplasm [27] (Fig. 1A).  
 
Initially EGFP was used as a foreign gene for a proof-of-concept experiment. Four 
plasmids harbouring an identical EGFP gene between an IRESEMCV element and a 
polyadenylation signal were constructed. EGFP gene was under the control of CMV promoter 
in pSD-EGFP, T7 promoter in pSR-EGFP, and a dual promoter in pSDR-EGFP. Plasmid 
pIKT-EGFP used both CMV and T7 promoters to control EGFP expression and had a T7 
RNAP autogene cassette [28] (Fig. 1B). Kinetics of fluorescence expression in the cells 
following ST3-mediated delivery of an IKDE system versus the delivery of the other plasmids 
was evaluated (Fig. 1C). ST3/pIKT-EGFP produced the highest fluorescence intensity at all 
time points, with >10-fold increase in gene expression compared to plasmid DNA 
(pSD-EGFP) or DNA/RNA dual delivery (pSR-EGFP, pSDR-EGFP). Furthermore, we tested 
the effects of a series of inhibitors including prokaryotic mRNA transcription inhibitor 
(Rifampicin), eukaryotic transcription inhibitor (Amanitin), translation inhibitor 
(Cycloheximide) or cell cycle inhibitor (Thymidine) on reporter gene expression after 
infection and found that synthesis of EGFP observed by ST3/pIKT-EGFP infection with was 
mainly mediated by the direct eukaryotic translation of EGFP mRNA transcribed by the T7 
RNAPs. Collectively, incorporation of T7 RNAP-based autocatalytic feedback loop enables a 
stable and continuous expression of EGFP assisted by self-amplification of the polymerases. 
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Fig. 1. Delivery strain ST3 carrying an IKDE system leads to rapid and high-level transgene 
expression in vitro. (A) Schematic diagram of the IKDE system. (1) In the bacterial cytosol, 
bacterial chromosome-produced T7 RNAPs bind to the T7 promoter and then mediate the 
efficient transcription of mRNAs (curve). (2) Upon intracellular delivery, functional mRNAs 
will be translated into T7 RNAP (orange triangle) or EGFP (green circle) in the cytoplasm, 
where an initial source of T7 RNAPs can prime a positive-feedback loop and over-express 
gene mRNA from pIKT-EGFP (circle). (3) A small percentage of plasmid DNA will enter the 
nucleus, where the transcription machinery will generate stable transcripts through the nuclear 
system. (B) RT-PCR detection of EGFP mRNA in ST3 harbouring the indicated vectors. (C) 
Expression kinetics was determined at 24, 48 and 72 h post infections. Average GFP 
concentration and SD of three experiments are shown. (D) Fluorescent intensity of infected 
cells 40 h after infection in the presence of various inhibitors, relative to the level obtained in 
untreated controls. * P<0.05, ** P<0.01. 
 
3.2. In vitro screening of potential therapeutic factors by ST3-mediated inter-kingdom gene 
transfer and RNAi 
Using this synthetic inter-kingdom expression platform, intracellular delivery and expression 
of various cargos could be achieved to assess their therapeutic potential. ST3 harbouring 
different therapeutic candidates (Table S3), either protein, DNA or RNA, were used to deliver 
their cargos into MDA-MB-231 breast cancer cells.  
 
When ST3 carrying a plasmid encoding therapeutic proteins, such as the catalytic fragment of 
diphtheria toxin (DTA), enters into the mammalian cells. Plasmids, T7 RNAP enzyme and 
translation-competent mRNA synthesized in the bacterium can pass into the cytoplasm, aided 
by the LLO generated pores, and then trigger the initial transcription of polymerases by the 
host (Fig. 2A). Driven by the T7 RNAP-autoactivation loop, gene expression substantially 
increases (Fig. 2B). Like therapeutic proteins, RNA therapeutic candidates, such as a shRNA 
against a cancer-related gene, can be delivered and transcribed from a similar plasmid, 
pIKT-shRNA, encoding a shRNA sequence under the control of T7 promoter. To evaluate the 
potency of ST3/pIKT-shRNA mediated knockdown of endogenous genes, a shRNA sequence 
shPlk, which targets a cell cycle-associated protein polo-like kinase 1 (PLK1) [29] was used 
(Fig. 2C). Quantitative real-time PCR was used to determine 6.89 ± 0.64 pg of shPlk present 
in 1 ng bacterial total RNA. By 48 h, ST3/pIKT-shPlk infection exhibited ~80% mRNA 
12 
 
inhibition and substantial protein reduction (Fig. 2D and E). A series of therapeutic factors 
were tested in vitro by measuring or monitoring physiological events such as cell death and 
proliferation (Fig. 2F). Lead candidates with relatively high potency were then evaluated in 
animal models. 
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Fig. 2. Inhibition of cell proliferation and induction of cell death by ST3-mediated 
inter-kingdom delivery and expression of a protein drug or hairpin RNA. (A) Human 
MDA-MB-231 cells were infected by ST3/pIKT-DTA or pIKT-EGFP. The cells were further 
cultured for 12 h before T7 RNAP, DT-A and GAPDH (control) transcripts were detected by 
RT-PCR. (B) The time course of DT-A expression was profiled for 48 h (n=3). (C) Plasmid 
diagram of pIKT-shPlk for transcription of shRNA against PLK1. (D) ~ 80% knockdown of 
target gene by ST3/pIKT-shPlk was verified by quantitative RT-PCR (n=4, **P<0.01). Data 
normalized to control values of 100%. (E) Western blot analysis confirmed the silencing 
effects on the protein levels. (F) Cell proliferation assay and Annexin-V/PI apoptosis analysis 
were assessed at 48 h post infections (n=3). All data are mean±SD.  
 
3.3. ST4/pIKT-DTA therapy reduces tumor burden and malignant ascites while extending 
survival in the immunocompetent mice with highly aggressive tumors 
Tumor-targeting Salmonella ST4 was modified from ST3 (Fig. S1), by placing the 
essential gene asd with a tightly hypoxic regulated control to program the bacterium only 
survive in anaerobic conditions (Fig. 3A), such as the hypoxic core of tumors (Fig. 3B). 
Injection of tumor-bearing nude mice with ST4 showed that the bacteria were 
replication-incompetent in normal organs but could amplify within tumors to as high as 10
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cfu per gram tissue (Fig. 3C). Safety of strain ST4 was demonstrated in the 
immunocompromised animals, which could tolerate and survive for long periods, unlike the 
same hosts when infected with the parental bacterial strain (Fig. 3D and E).  
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Fig. 3. The conversion of wild-type strain SL7207 to ST4 could target the hypoxic core inside 
solid tumor and prevent the bacterial killing of the mice. (A) Strains SL7207 and ST4 were 
grown on LB agar plates under aerobic (+O2) or anaerobic (-O2) conditions. (B) Composite 
images were generated for the whole tumor to observe macroscopic bacterial colonization. A 
detailed examination of the distribution of ST4 inside the tumors revealed that the bacteria 
were resisted to the hypoxic regions (Hyperxyprobe-1 labelled). Scale bar, 1 mm. (C) 
Preferential accumulation of ST4 within the tumors after an intravenous injection (n=3). ND, 
not detected. (D) Lack of nonspecific accumulation of ST4 in the liver made improved safety. 
Representative histopathologic and immunohistochemical staining of Salmonella on liver 
sections as indicated. N, necrotic area. Scale bar, 100 μm. (E) Kaplan-Meier survival curves 
of the immunocompromised mice receiving ST4 or wild-type Salmonella at a dose of 5×
10
7
cells/mouse. 
 
Next, we tested ST4 harbouring inter-kingdom dual expression of therapeutic proteins in 
an immunocompetent mouse model harbouring highly aggressive and metastatic breast cancer. 
4T1 multidrug-resistant murine tumor cells were implanted into the mammary fat pad of 
immunocompetent, syngeneic BALB/c mice, which were subsequently inoculated with 
ST4/pIKT-DTA. After 7 and 14 days post-injection, bacteria were only growing in primary 
tumors and metastatic nodules in the lung and not found in normal tissues (Fig. 4A).  
 
By day 2, production of DT-A was observed and its expression level was stably 
maintained over 2 weeks, after which the mice were sacrificed and primary tumors were 
harvested (Fig. 4B). Intracellular presence of bacterial toxins (red) in the cytosol of 
ST4/pIKT-DTA (green) infected cells, but not in ST4/pIKT-null infected counterparts was 
revealed by immunofluoresence and DAPI staining (Fig. 4C) and by western blot analysis 
(Fig. 4D). Immunohistochemical assay of tumor sections showed that polypeptides were 
diffused around the bacteria with some molecules transferred to the viable rim (Fig. S4). Total 
RNA was reverse transcribed using the target gene specific reverse anchor primer. Data 
showed that 92.7 ± 1.7% of the transcripts were driven by the T7 RNAP-based cytoplasmic 
expression, with the remainder driven by the nuclear specific CMV promoter.  
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Fig. 4. Tumor-targeting Salmonella ST4 allows the precise expression of suicide gene in 
immunocompetent animals. (A) Bacterial accumulation in the tumors and normal tissues were 
determined 7 and 14 days later. Bars correspond to mean ± SD (n=3). ND, not detected. (B) 
Kinetics of DT-A expression over 2 weeks after a single ST4/pIKT-DTA injection. (C-D) 
Detection of suicide gene expression in the ST4/pIKT-DTA treated tumors by fluorescent 
immunostaining (C) and western blot analysis (D). (C) Tumor sections were stained for 
intracellular pore-forming LLO (green) and DT A chain (red). Scale bar, 25 μm.  
 
In situ expression of DT A chain caused a much greater proportion of necrotic areas, 
significant cell death (1.8 ± 0.18 fold increase in TUNEL-positive cells) and an almost 
complete absence of proliferating Ki67-positive cells (Fig. 5A), compared to a control agent. 
Moreover, there were significant reductions in pulmonary metastases (P=0.025) in mouse 
models relative to ST4/pIKT-EGFP treatment (Fig. 5B), which had a slight inhibitory effect. 
Evidence to destruct tumor microenvironment by ST4/pIKT-DTA was also provided by 
CD105-immunohistochemical staining, indicating the destruction of blood vessels (Fig. S5).  
Synergistic effects of attenuated Salmonella and the inter-kingdom system allowed the 
precise expression of DT A chain in tumor microenvironment and eradicated large established 
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tumors (Fig. S6). Another group consisted of animals carrying tumors of about 200~250 mm
3
, 
which was found to be optimal for bacterial treatment. A single injection 5×106 of 
ST4/pIKT-DTA resulted in sustained regression over four weeks (Fig. 5C) and complete 
survival, whereas mice treated with PBS or ST4/pIKT-EGFP did not survive (Fig. 5D). 
Collectively, these experiments showed that ST4/pIKT-DTA treatment was effective in tumor 
shrinkage and greatly reduced the risk of death.  
19 
 
 
20 
 
Fig. 5. Potent therapeutic effects in immunocompetent mice with highly aggressive tumors 
elicited by ST4-mediated expression of diphtheria toxin. (A) Anti-tumor effects were 
examined by histological examination, apoptosis by TUNEL labelling and proliferation by 
Ki67 expression of primary tumors from ST4/pIKT-EGFP and ST4/pIKT-DTA treated mice. 
Viable regions are marked with V and the necrotic area by N. Scale bars, 500 μm for H&E 
staining; 50 μm for TUNEL and Ki67 staining. (B) Representative photographs of pulmonary 
metastases from mice treated as described above. Arrows indicate lung metastases. Scale bars, 
1 cm for bright field imaging; 250 μm for H&E staining. Each dot represents the number of 
nodules per mouse. (C) On 12 day after tumor implantation, PBS, ST4/pIKT-EGFP or 
ST4/pIKT-DTA were intravenously injected to BALB/c mice with 4T1 breast tumors (n=5). 
Primary tumor volumes were measured every other day. (D) Kaplan-Meier survival curves of 
the animals administered with the indicated treatments (n=8), showing 100% survival only in 
the mice receiving ST4/pIKT-DTA treatment. All data are mean±SD. * P<0.05, ** P<0.01. 
 
3.4. ST4-mediated inter-kingdom RNAi in vivo 
We also demonstrated that ST4 packaged with shRNA-encoding plasmids has sustained 
knockdown effects in nude mice bearing human MDA-MB-231 xenografts. At three weeks 
after treatments, expression of T7 RNAP in the tumors, as confirmed by quantitative RT-PCR 
(159.1 ± 67.4 copies/ng RNA), was high and, as intended, led to enhanced shRNA production 
compared to inoculation with a system lacking this expression ability (ST4/pIKT△T7P-shPlk) 
(Fig. 6A). PLK1 transcript levels in tumors treated with ST4/pIKT-shPlk were 75.5 ± 11.5% 
(P=0.002) and 62.5 ± 18.6% (P=0.015) lower than those in mice injected with PBS (mock 
control) or ST4/pIKT-shTom (vector control) (Fig. 6B). The presence of PLK1 5′ RACE-PCR 
cleavage products confirmed a sustained RNAi-mediated mechanism of action (Fig. 6C, top). 
A clear reduction of PLK1 protein level was shown by western blot analysis (Fig. 6C, bottom) 
and immunohistochemical assay (Fig. 6D) only for ST4/pIKT-shPlk treated mice. No 
statistically significant induction of the interferon-inducible gene OAS1 (encoding 2’, 
5’-oligoadenlylate synthetases) (P=0.16) was detected between ST4/pIKT-shTom and 
ST4/pIKT-shPlk treated mice, suggesting cytokine induction was not responsible for the 
observed knockdown effects. On day 20, tumor growth was restricted such that the tumor 
sizes in mice injected with PBS, ST4/pIKT-shTom and ST4/pIKT-shPlk were 2137.4 ± 170.2 
mm
3
, 1425.3± 136.0 mm
3
 and 836.5 ± 166.7 mm
3
, respectively, with ST4/pIKT-shPlk treated 
tumor sizes significantly smaller than those treated with ST4/pIKT-shTom (P<0.001) (Fig. 
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6E). These results suggest that the ST4-mediated inter-kingdom RNAi induces a potent, 
specific and continuous gene silencing in solid tumors after a single injection. 
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Fig. 6. Tumor-targeting ST4-mediated combinational inter-kingdom RNAi in vivo. (A) 
Quantitative stem-loop RT-PCR of shPlk1 levels in ST4/pIKT-shPlk and 
ST4/pIKR△T7P-shPlk (without T7 RNAP autogene cassette) treated tumors (n=7). (B) 
Real-time PCR quantification of the reduction of PLK1 mRNA after the indicated treatments 
(n=4). (C) Upper panel: In vivo 5’-RACE analysis of RNA extracted from ST4/pIKT-shPlk 
tumors confirmed the presence of specific cleaved product (414 bp). Lower panel: Western 
blot analysis of Plk1 and Tubulin protein levels in three groups. (D) Primary tumors were 
assessed by histological and immunohistochemical analyses. Sections stained with H&E (top) 
or probed with Plk1 antibody (bottom). Scale bar, 50 μm. (E) Tumor growth curves of mice 
(n=5 per group) treated with PBS, ST4/pIKT-shTom or ST4/pIKT-shPlk. All results are 
referred to mean±SD. ** P<0.01.  
 
3.5. Systemic toxicity testing of ST4 harboring inter-kingdom therapeutic system to express 
cytotoxic proteins or shRNA 
To evaluate the health status of mice during the bacterial treatments, the body weight and 
appearance of mice were monitored every other day. Body weight lost in the first 2~4 days 
and then recovered to the normal conditions during a 20-day observation period (Fig. 7A). All 
the mice have been sacrificed on day 20. Mice had slight enlarged spleens due to slight 
hematopoiesis (Fig. 7B). Serum ALT, AST and BUN levels in all treatment groups were in 
the normal range (Fig. 7C and D), which indicated no detectable hepatic stress or kidney 
injury. To investigate whether the bacterial infection or therapeutic molecules caused any 
pathological damages in the major organs, the sections of normal tissues have been processed 
for H&E staining (Fig. 7E). Gross morphological examination showed that there were no 
detectable abnormal nodules and apoptotic cell death in the selected organs. These indicated 
that systemic administration of one injection of ST4/pIKT-DTA or ST4/pIKT-shPlk was well 
tolerated at the dose level tested (5×106 cells/mouse) and the observed antitumor effects 
were unlikely related to toxic effects. 
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Fig. 7. Systemic toxicity testing of bacterial treatments. Body weight (A) and spleen weights 
(B) of tumor-bearing nude mice received with PBS, ST4/pIKT-shPlk or ST4/pIKT-DTA 
treatments. NS, no statistical significance. (C-D) Serum ALT, AST and BUN levels were 
measured by standard methods. Values are mean ± SD for 3 animals. (E) No apparent damage 
was found in any of the organs in either treatment group. Scale bar, 50 μm.  
 
4. Discussion and conclusion 
In the past decade, selected bacteria have been exploited as a tiny programmable robot 
factory and made great strides. Despite of a growing number of bacterial species that 
apparently exhibit intrinsic tumor-targeting properties, these bacteria generally been found to 
effective only against relatively small tumors in studies, and no bacterium that is able to 
inhibit tumor growth completely in fully immunocompetent hosts [30-36]. Our present study 
provides a considerable improvement over earlier technologies [13, 34, 37-39], in terms of 
safety, stability, flexibility and efficiency, and the following will highlight some reasons.  
  Some engineered Salmonella have exerted inherent tumor repression ability in many 
types of tumor models [33-36]. These attenuated Salmonella preferentially colonizes various 
human tumors; however, such bacteria would also colonize spleen and liver, achieving 
tumor-to-normal tissue accumulation ratios of 1000:1. This biodistribution may cause 
undesired side effects. To reduce intrinsic bacterial toxicity and achieve precise targeting of 
tumor microenvironment, a series of genetic manipulations based on the rational designed 
circuits has been made. After two or three weeks following injection, bacteria were barely 
detectable in normal organs (Fig. 3 C and D). These bacteria selectively grew within the 
primary tumors and also target to the metastases (Fig. 4A), which has been shown to be 
non-pathogenic in both immunocompetent and immunocompromised hosts (Fig. 3 D and E), 
suggesting that it is considered safe enough for therapeutic uses. In addition, our system is 
superior to previous bacterial systems in term of in vivo stability [12, 13]. Firstly, the bacterial 
factors involved in tumor fitness, intracellular delivery and expression were integrated into 
the chromosome. Secondly, we used a plasmid encoding a functional translation initiation 
factor1 from E. coli as selection marker and show that the expression vectors can be 
maintained in the Salmonella carriers at high copies in vivo (Table S4). This system is tightly 
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regulated due to no-cross feeding effects, which is superior to a selection system based on 
complementation of host auxotrophy [40].  
The versatility of this inter-kingdom system was demonstrated by the use of a reporter 
gene as a proof of concept. Then the potent therapeutic results have been obtained through the 
synergistic antitumor effects of intrinsic bacterial toxicity plus the inter-kingdom expression 
of versatile therapeutic factors: bacterial toxins leading to cell death; and constructs for 
shRNA resulting in RNAi after processing in the target cells, as shown against the cell-cycle 
gene (PLK1). It was particularly notable that endowing these targeted bacteria to produce DT 
A chain greatly increase their antitumor activity in the immunocompetent animals, as 
determined in both subcutaneous primary tumor and lung metastases (Fig. 5). The likely 
reason for the improved inhibitory effect is that the killing-mediated by diphtheria toxin is 
direct and strong enough to eradicate multiple cell types, including the inflammatory cells and 
endothelial cells (Fig. S5), and subsequently destroy the tumor microenvironment. In the 
experiments reported here, a single dose of ST4/pIKT-DTA induced remarkable tumor 
shrinkage and cured 26% of cases (n=5/19). 
Compared to the previously reported bacteria-mediated trans-kingdom RNAi [13], our 
technology has three improvements: (1) high tumor-targeting characteristics, (2) in vivo 
plasmid maintenance, (3) combination of prokaryotic and eukaryotic transcription of shRNA. 
In vivo studies suggested that ST4-mediated inter-kingdom RNAi system has achieved a 
stronger silencing ability and reduce total adverse effects (Fig. S7).  
A series of pathological observations were also made to exclude non-specific toxicity of 
the above treatments being responsible for the observed effects (Fig. 7). Taken together, this 
combined bacterial and eukaryotic plasmid system may also have a place alongside 
established treatment and vaccination protocols. 
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Figure legends 
 
Fig. 1. Delivery strain ST3 carrying an IKDE system leads to rapid and high-level transgene 
expression in vitro. (A) Schematic diagram of the IKDE system. (1) In the bacterial cytosol, 
bacterial chromosome-produced T7 RNAPs bind to the T7 promoter and then mediate the 
efficient transcription of mRNAs (curve). (2) Upon intracellular delivery, functional mRNAs 
will be translated into T7 RNAP (orange triangle) or EGFP (green circle) in the cytoplasm, 
where an initial source of T7 RNAPs can prime a positive-feedback loop and over-express 
gene mRNA from pIKT-EGFP (circle). (3) A small percentage of plasmid DNA will enter the 
nucleus, where the transcription machinery will generate stable transcripts through the nuclear 
system. (B) RT-PCR detection of EGFP mRNA in ST3 harbouring the indicated vectors. (C) 
Expression kinetics was determined at 24, 48 and 72 h post infections. Average GFP 
concentration and SD of three experiments are shown. (D) Fluorescent intensity of infected 
cells 40 h after infection in the presence of various inhibitors, relative to the level obtained in 
untreated controls. * P<0.05, ** P<0.01. 
 
Fig. 2. Inhibition of cell proliferation and induction of cell death by ST3-mediated 
inter-kingdom delivery and expression of a protein drug or hairpin RNA. (A) Human 
MDA-MB-231 cells were infected by ST3/pIKT-DTA or pIKT-EGFP. The cells were further 
cultured for 12 h before T7 RNAP, DT-A and GAPDH (control) transcripts were detected by 
RT-PCR. (B) The time course of DT-A expression was profiled for 48 h (n=3). (C) Plasmid 
diagram of pIKT-shPlk for transcription of shRNA against PLK1. (D) ~ 80% knockdown of 
target gene by ST3/pIKT-shPlk was verified by quantitative RT-PCR (n=4, **P<0.01). Data 
normalized to control values of 100%. (E) Western blot analysis confirmed the silencing 
effects on the protein levels. (F) Cell proliferation assay and Annexin-V/PI apoptosis analysis 
were assessed at 48 h post infections (n=3). All data are mean±SD.  
 
Fig. 3. The conversion of wild-type strain SL7207 to ST4 could target the hypoxic core inside 
solid tumor and prevent the bacterial killing of the mice. (A) Strains SL7207 and ST4 were 
grown on LB agar plates under aerobic (+O2) or anaerobic (-O2) conditions. (B) Composite 
images were generated for the whole tumor to observe macroscopic bacterial colonization. A 
detailed examination of the distribution of ST4 inside the tumors revealed that the bacteria 
were resisted to the hypoxic regions (Hyperxyprobe-1 labelled). Scale bar, 1 mm. (C) 
Preferential accumulation of ST4 within the tumors after an intravenous injection (n=3). ND, 
not detected. (D) Lack of nonspecific accumulation of ST4 in the liver made improved safety. 
Representative histopathologic and immunohistochemical staining of Salmonella on liver 
sections as indicated. N, necrotic area. Scale bar, 100 μm. (E) Kaplan-Meier survival curves 
of the immunocompromised mice receiving ST4 or wild-type Salmonella at a dose of 5×
10
7
cells/mouse. 
 
Fig. 4. Tumor-targeting Salmonella ST4 allows the precise expression of suicide gene in 
immunocompetent animals. (A) Bacterial accumulation in the tumors and normal tissues were 
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determined 7 and 14 days later. Bars correspond to mean ± SD (n=3). ND, not detected. (B) 
Kinetics of DT-A expression over 2 weeks after a single ST4/pIKT-DTA injection. (C-D) 
Detection of suicide gene expression in the ST4/pIKT-DTA treated tumors by fluorescent 
immunostaining (C) and western blot analysis (D). (C) Tumor sections were stained for 
intracellular pore-forming LLO (green) and DT A chain (red). Scale bar, 25 μm.  
 
Fig. 5. Potent therapeutic effects in immunocompetent mice with highly aggressive tumors 
elicited by ST4-mediated expression of diphtheria toxin. (A) Anti-tumor effects were 
examined by histological examination, apoptosis by TUNEL labelling and proliferation by 
Ki67 expression of primary tumors from ST4/pIKT-EGFP and ST4/pIKT-DTA treated mice. 
Viable regions are marked with V and the necrotic area by N. Scale bars, 500 μm for H&E 
staining; 50 μm for TUNEL and Ki67 staining. (B) Representative photographs of pulmonary 
metastases from mice treated as described above. Arrows indicate lung metastases. Scale bars, 
1 cm for bright field imaging; 250 μm for H&E staining. Each dot represents the number of 
nodules per mouse. (C) On 12 day after tumor implantation, PBS, ST4/pIKT-EGFP or 
ST4/pIKT-DTA were intravenously injected to BALB/c mice with 4T1 breast tumors (n=5). 
Primary tumor volumes were measured every other day. (D) Kaplan-Meier survival curves of 
the animals administered with the indicated treatments (n=8), showing 100% survival only in 
the mice receiving ST4/pIKT-DTA treatment. All data are mean±SD. * P<0.05, ** P<0.01. 
 
Fig. 6. Tumor-targeting ST4-mediated combinational inter-kingdom RNAi in vivo. (A) 
Quantitative stem-loop RT-PCR of shPlk1 levels in ST4/pIKT-shPlk and 
ST4/pIKR△T7P-shPlk (without T7 RNAP autogene cassette) treated tumors (n=7). (B) 
Real-time PCR quantification of the reduction of PLK1 mRNA after the indicated treatments 
(n=4). (C) Upper panel: In vivo 5’-RACE analysis of RNA extracted from ST4/pIKT-shPlk 
tumors confirmed the presence of specific cleaved product (414 bp). Lower panel: Western 
blot analysis of Plk1 and Tubulin protein levels in three groups. (D) Primary tumors were 
assessed by histological and immunohistochemical analyses. Sections stained with H&E (top) 
or probed with Plk1 antibody (bottom). Scale bar, 50 μm. (E) Tumor growth curves of mice 
(n=5 per group) treated with PBS, ST4/pIKT-shTom or ST4/pIKT-shPlk. All results are 
referred to mean±SD. ** P<0.01.  
 
Fig. 7. Systemic toxicity testing of bacterial treatments. Body weight (A) and spleen weights 
(B) of tumor-bearing nude mice received with PBS, ST4/pIKT-shPlk or ST4/pIKT-DTA 
treatments. NS, no statistical significance. (C-D) Serum ALT, AST and BUN levels were 
measured by standard methods. Values are mean ± SD for 3 animals. (E) No apparent damage 
was found in any of the organs in either treatment group. Scale bar, 50 μm.  
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Supplementary materials 
Table S1. Bacterial strains and plasmids used in this study. 
Table S2. Oligonuclotides used in this study.  
Table S3. Potential candidates tested in vitro. 
Table S4. Estimate plasmid pcDNA3.1-infA copy numbers by relative qualification.  
Fig. S1. Generation of a tumor-targeting Salmonella strain ST4 for delivery and expression of 
multiple therapeutic factors. 
Fig. S2. Relative fluorescence intensity in the cells infected by ST3 or ST5 carrying 
commercial plasmid pDsred. 
Fig. S3. Fluorescence-activated cell sorting was used to demonstrate EGFP expression after 
48 h following bacterial infections. 
Fig. S4. Composite images of a whole tumour infected with ST4/pIKT-DTA stained to 
visualize bacteria (left) and cytotoxic DT A chain (right).  
Fig. S5. Injection of ST4/pIKT-DTA significantly retards tumor angiogenesis. 
Fig. S6. Potent regression of large established tumors in mice treated with ST4/pIKT-DTA. 
Fig. S7. Comparison of anti-tumor effects between tkRNAi system (E/TRIP-shRNA) and our 
system (S/pIKT-shRNA). 
 
 
 
